752965-91-6 Usage
Chemical structure
A compound consisting of a piperidine ring fused to a benzene ring, with a pyridine ring attached to the piperidine and a carbonitrile group at the 4-position.
Pharmacological applications
Potential use in the treatment of psychiatric disorders and neurological diseases.
Receptor activity
Exhibits potent activity as a ligand for certain receptors in the central nervous system.
Drug development
Considered a potential candidate for drug development due to its receptor activity and unique chemical structure.
Research tool
Valuable for research in the field of medicinal chemistry due to its unique chemical structure and properties.
Therapeutic agent
Shows promise as a potential therapeutic agent in the pharmaceutical industry.
Molecular weight
Approximately 330 g/mol (calculated from the molecular formula).
Appearance
Likely a solid, based on the molecular weight and structure.
Solubility
Solubility properties are not provided, but it is likely to be soluble in organic solvents such as methanol, ethanol, or dimethyl sulfoxide (DMSO), as these are common solvents for similar compounds.
Stability
Stability information is not provided, but it is generally expected that such compounds are stable under normal laboratory conditions.
Synthesis
The synthesis method is not provided, but it is likely synthesized through a series of chemical reactions involving the formation of the piperidine ring, attachment of the benzyl and pyridin-3-yl groups, and the introduction of the carbonitrile group.
Purity
Purity information is not provided, but it is important to ensure that the compound is synthesized and purified to a high level for both research and therapeutic applications.
Safety and handling
Safety and handling information is not provided, but it is crucial to follow proper laboratory safety protocols when working with 1-Benzyl-4-(pyridin-3-yl)piperidine-4-carbonitrile, including the use of personal protective equipment (PPE) and handling in a well-ventilated area or fume hood.
Check Digit Verification of cas no
The CAS Registry Mumber 752965-91-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,2,9,6 and 5 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 752965-91:
(8*7)+(7*5)+(6*2)+(5*9)+(4*6)+(3*5)+(2*9)+(1*1)=206
206 % 10 = 6
So 752965-91-6 is a valid CAS Registry Number.
752965-91-6Relevant articles and documents
Substituted Sulfonamide Compounds
-
Page/Page column 92, (2009/10/17)
Substituted sulfonamide compounds corresponding to the formula I: processes for the preparation thereof, pharmaceutical composition containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions.
Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists
Burkholder, Timothy P.,Kudlacz, Elizabeth M.,Maynard, George D.,Liu, Xiao-Gao,Le, Tieu-Binh,Webster, Mark E.,Horgan, Stephen W.,Wenstrup, David L.,Freund, David W.,Boyer, Fred,Bratton, Larry,Gross, Raymond S.,Knippenberg, Robert W.,Logan, Deborah E.,Jones, Bryan K.,Chen, Teng-Man,Geary, Julie L.,Correll, Melinda A.,Poole, J. Chuck,Mandagere, Arun K.,Thompson, Thomas N.,Hwang, Kin-Kai
, p. 2531 - 2536 (2007/10/03)
We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors. Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration.
